Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Long-Term Investments (2016 - 2019)

VYNE Therapeutics' Long-Term Investments history spans 4 years, with the latest figure at $2.0 million for Q3 2019.

  • For Q3 2019, Long-Term Investments changed N/A year-over-year to $2.0 million; the TTM value through Sep 2019 reached $2.0 million, changed N/A, while the annual FY2017 figure was $3.0 million, 71.42% down from the prior year.
  • Long-Term Investments reached $2.0 million in Q3 2019 per VYNE's latest filing, down from $10.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $20.7 million in Q1 2018 to a low of $2.0 million in Q3 2019.
  • Average Long-Term Investments over 4 years is $9.3 million, with a median of $10.4 million recorded in 2016.
  • The largest YoY upside for Long-Term Investments was 71.42% in 2017 against a maximum downside of 71.42% in 2017.
  • A 4-year view of Long-Term Investments shows it stood at $10.4 million in 2016, then tumbled by 71.42% to $3.0 million in 2017, then soared by 250.07% to $10.4 million in 2018, then plummeted by 80.78% to $2.0 million in 2019.
  • Per Business Quant, the three most recent readings for VYNE's Long-Term Investments are $2.0 million (Q3 2019), $10.4 million (Q2 2018), and $20.7 million (Q1 2018).